« Return to News | Awards & Advancement

Harlan CRS Cytotest Cell Research in EU-NETVAL

Friday, August 9, 2013 01:58 PM

Germany-based Harlan Contract Research Services (CRS) Cytotest Cell Research has been selected for inclusion in the E.U. Network of Laboratories for the Validation of Alternative Methods (EU-NETVAL). EU-NETVAL provides support for the E.U. Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) to develop methods to reduce, refine or replace animals used for scientific purposes.

“Being in the initial group of laboratories acknowledges the expertise of our scientists as well as our continuous work in and support for alternative in vitro methodologies, including our participation in E.U. validation projects in the past,” said Dr. Albrecht Poth, deputy managing director and scientific advisor for Harlan.

The aim of EURL ECVAM is to promote the scientific and regulatory acceptance of non-animal tests and to coordinate the independent evaluation of tests for specific purposes. Harlan will contribute to the development of guidance documents, procedures, training materials and collaboration tools that facilitate the development, validation and acceptance of alternative methods.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.